Mirum Pharmaceuticals
Ways of working, last update 1 day ago
Pharma biotech · Headquarters United States
Everything we hold on Mirum Pharmaceuticals, newest first. Every line links to the filing or report it came from.
- 2026-08-15Headcount Not Stated Ways of working
Mirum Pharmaceuticals advertises 100% of its open roles as fully remote
What an employer advertises is the offer a candidate can accept today. It moves before any return-to-office announcement, because a policy reaches the job postings before it reaches a press release. Read it as the shape of the roles being hired for, not of the whole workforce, and read the direction rather than the exact share.
- 2026-08-04Adding Roles Growing and expanding
Mirum Pharmaceuticals opened 7 more roles in remote roles (job board: 35 to 42)
A board that grows week on week is the earliest public evidence of hiring intent an employer produces: it moves before any announcement and before any filing. Treat the direction as the signal and the exact count as approximate, since roles are reposted, split across locations and withdrawn without notice.
- 2026-01-29Headcount Not Stated Growing and expanding
Mirum Pharmaceuticals, Inc. raised $68.5M in a private placement
Mirum Pharmaceuticals, Inc. reported a $68.5M private placement to the SEC on 2026-01-29, listing an address in CA. The filing records the money only; it names no roles and no hiring plan.
- 2025-12-31Pay Change Pay and benefits
Mirum Pharmaceuticals, Inc.: $10,441,224 total compensation for the principal executive officer, fiscal year ended 2025-12-31
Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.
- 2024-12-31Pay Change Pay and benefits
Mirum Pharmaceuticals, Inc.: $6,598,551 total compensation for the principal executive officer, fiscal year ended 2024-12-31
Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.
- 2023-12-31Pay Change Pay and benefits
Mirum Pharmaceuticals, Inc.: $6,451,720 total compensation for the principal executive officer, fiscal year ended 2023-12-31
Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.
- 2022-12-31Pay Change Pay and benefits
Mirum Pharmaceuticals, Inc.: $4,402,664 total compensation for the principal executive officer, fiscal year ended 2022-12-31
Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.
The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker